MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, AMPH made $171,171K in revenue. $6,420K in net income. Net profit margin of 3.75%.

Income Overview

Revenue
$171,171K
Net Income
$6,420K
Net Profit Margin
3.75%
EPS
$0.14
Unit: Thousand (K) dollars
Revenue Breakdown
    • Other Products
    • Baqsimi
    • Primatenemist
    • Others
Revenue Breakdown
    • US
    • FR
    • CN

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
171,171 183,105 191,840 174,414
Cost of revenues
100,849 97,435 93,194 87,924
Gross profit
70,322 85,670 98,646 86,490
Selling, distribution, and marketing
11,927 10,279 11,505 10,235
General and administrative
18,028 16,471 39,467 13,991
Research and development
26,737 23,314 22,354 20,080
Total operating expenses
56,692 50,064 73,326 44,306
Income from operations
13,630 35,606 25,320 42,184
Interest income
2,400 2,423 2,246 1,921
Interest expense
6,553 6,630 6,284 6,281
Other income (expenses), net
575 515 231 1,511
Total non-operating income (expenses), net
-3,578 -3,692 -3,807 -2,849
Income before income taxes
10,052 31,914 21,513 39,335
Income tax provision
3,632 7,485 4,163 8,305
Income before equity in losses of unconsolidated affiliate
-24,429 17,350 31,030
Net income
6,420 24,429 17,350 31,030
Basic EPS
0.14 0.532 0.38 0.66
Diluted EPS
0.14 0.518 0.37 0.64
Basic Average Shares
45,322,000 45,908,000 46,474,000 46,949,000
Diluted Average Shares
46,458,000 47,165,000 47,677,000 48,128,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Other Products$67,131K (34.13%↑ Y/Y)Baqsimi$32,434K (-15.44%↓ Y/Y)Primatenemist$29,763K (2.45%↑ Y/Y)Epinephrine$19,213K (3.37%↑ Y/Y)Lidocaine$13,460K (-1.35%↓ Y/Y)Glucagon$9,170K (-56.00%↓ Y/Y)Revenues$171,171K (0.38%↑ Y/Y)Gross profit$70,322K (-17.51%↓ Y/Y)Cost of revenues$100,849K (18.26%↑ Y/Y)Income from operations$13,630K (-63.45%↓ Y/Y)Total operatingexpenses$56,692K (18.21%↑ Y/Y)Income before incometaxes$10,052K (-67.43%↓ Y/Y)Total non-operatingincome (expenses), net-$3,578K (44.36%↑ Y/Y)Interest income$2,400K (14.89%↑ Y/Y)Other income(expenses), net$575K (125.74%↑ Y/Y)Research and development$26,737K (33.05%↑ Y/Y)General andadministrative$18,028K (12.70%↑ Y/Y)Selling, distribution,and marketing$11,927K (0.51%↑ Y/Y)Net income$6,420K (-74.61%↓ Y/Y)Income tax provision$3,632K (-34.88%↓ Y/Y)Interest expense$6,553K (4.25%↑ Y/Y)

Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals, Inc. (AMPH)